pSivida Reports Updates on Iluvien for Planned Resubmission to FDA and European Launch
WATERTOWN, Mass.–(BUSINESS WIRE)–Mar 22, 2013 – pSivida Corp., a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that its licensee Alimera Sciences, Inc….
pSivida Reports Updates on Iluvien for Planned Resubmission to FDA and European Launch Read More »